Latest Industry Insights

We spoke to Prof. Oscar Ces, head of the Department of Chemistry at Imperial College London (ICL), to find out about the evolution of ICL’s White City Campus, the Agilent Measurement Suite and what it means for scientists across the board.

Cutting-edge mass spectrometry proteomics technologies are accelerating the discovery and validation of novel targets in cancer, opening up new avenues for next-generation cancer therapeutics.

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

At ASMS 2023, Technology Networks spoke with Jim Yano, senior director of product management at Thermo Fisher Scientific, to learn more about the company's novel instrument launches and how they could be applied to personalized medicine.

Unlocking more information from our proteome could deepen our understanding of disease, improve detection and influence drug selection. To find out more about single-molecule proteomics, we spoke to Parag Mallick, co-founder of Nautilus Biotech.

At the 71st Annual Society for Mass Spectrometry (ASMS) meeting, Technology Networks had the pleasure of speaking with Rohan Thakur, president of Life Sciences Mass Spectrometry at Bruker Daltonics. We discussed the new product launches from Bruker and focused specifically on the applications of the company’s newest mass spectrometer, the timsTOF Ultra, for immunopeptidomics.

The 10-year anniversary of SWATH DIA signifies a period of immense growth that is only expected to continue to evolve, influencing a wide range of fields. This article explores key milestones for SWATH DIA since its development.

To find out more about how proteomics is providing new insights into cancer dynamics and resistance mechanisms, we spoke to Dr. Ofer Sharon, CEO of OncoHost, a precision diagnostics company.

Technology Networks spoke with Anjali Pradhan, senior vice president of product management at Mission Bio, to discuss a new application for DNA methylation analysis, and its potential in uncovering new biological insights and biomarkers that may guide the future of cancer research.

This article will cover innovations in structural proteomics, a new way to identify drug targets across the proteome, a new method to dissect drug–protein interactions and the future of structure-based drug design.